Curevac Nv Stock Cash And Equivalents
| 5CV Stock | EUR 3.65 0.07 1.88% |
CureVac NV fundamentals help investors to digest information that contributes to CureVac NV's financial success or failures. It also enables traders to predict the movement of CureVac Stock. The fundamental analysis module provides a way to measure CureVac NV's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CureVac NV stock.
CureVac |
CureVac NV Company Cash And Equivalents Analysis
CureVac NV's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current CureVac NV Cash And Equivalents | 1.33 B |
Most of CureVac NV's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CureVac NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, CureVac NV has 1.33 B in Cash And Equivalents. This is 62.02% higher than that of the Healthcare sector and 197.46% higher than that of the Biotechnology industry. The cash and equivalents for all Germany stocks is 50.78% higher than that of the company.
CureVac Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CureVac NV's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CureVac NV could also be used in its relative valuation, which is a method of valuing CureVac NV by comparing valuation metrics of similar companies.CureVac NV is currently under evaluation in cash and equivalents category among its peers.
CureVac Fundamentals
| Return On Equity | -0.19 | |||
| Return On Asset | -0.34 | |||
| Profit Margin | (1.26) % | |||
| Operating Margin | (7.27) % | |||
| Current Valuation | 792.23 M | |||
| Shares Outstanding | 221.98 M | |||
| Shares Owned By Insiders | 45.68 % | |||
| Shares Owned By Institutions | 19.07 % | |||
| Price To Book | 2.07 X | |||
| Price To Sales | 13.59 X | |||
| Revenue | 102.99 M | |||
| Gross Profit | (135.09 M) | |||
| EBITDA | (386.49 M) | |||
| Net Income | (411.72 M) | |||
| Cash And Equivalents | 1.33 B | |||
| Cash Per Share | 7.34 X | |||
| Total Debt | 55.28 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 5.61 X | |||
| Book Value Per Share | 3.29 X | |||
| Cash Flow From Operations | (733.13 M) | |||
| Earnings Per Share | (0.63) X | |||
| Target Price | 72.97 | |||
| Number Of Employees | 764 | |||
| Beta | 2.93 | |||
| Market Capitalization | 1.85 B | |||
| Total Asset | 1.16 B | |||
| Z Score | 19.8 | |||
| Net Asset | 1.16 B |
About CureVac NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CureVac NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CureVac NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CureVac NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Additional Information and Resources on Investing in CureVac Stock
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in CureVac Stock please use our How to Invest in CureVac NV guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.